Heather Gordish-Dressman

Dr. Heather Gordish-Dressman

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
DMDavi A.G. Mázala
Davi A.G. Mázala
JNJames S. Novak
James S. Novak
MHMarshall W. Hogarth
Marshall W. Hogarth
MNMarie Nearing
Marie Nearing
PAPrabhat Adusumalli
Prabhat Adusumalli
TPTerence A. Partridge
Terence A. Partridge
Duchenne muscular dystrophy (DMD) is a chronic muscle disease characterized by poor myogenesis and replacement of muscle by extracellular matrix. Despite the shared genetic basis, severity of these deficits varies among patients. One source of these variations is the genetic modifier that leads to increased TGF-β activity. While anti–TGF-β therapies are being developed to target muscle fibrosis, their effect on the myogenic deficit is underexplored. Our analysis of in vivo myogenesis in mild (C57BL/10ScSn- mdx /J and C57BL/6J- mdx Δ 52 ) and severe DBA/2J- mdx (D2- mdx ) dystrophic models reveals no defects in developmental myogenesis in these mice. However, muscle damage at the onset of disease pathology, or by experimental injury, drives up TGF-β activity in the severe, but not in the mild, dystrophic models. Increased TGF-β activity is accompanied by increased accumulation of fibroadipogenic progenitors (FAPs) leading to fibro-calcification of muscle, together with failure of regenerative myogenesis. Inhibition of TGF-β signaling reduces muscle degeneration by blocking FAP accumulation without rescuing regenerative myogenesis. These findings provide in vivo evidence of early-stage deficit in regenerative myogenesis in D2- mdx mice and implicates TGF-β as a major component of a pathogenic positive feedback loop in this model, identifying this feedback loop as a therapeutic target.

3 March 2009 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
CSChristopher F. Spurney
Christopher F. Spurney
HGHeather Gordish-Dressman
Heather Gordish-Dressman
AGAlfredo D. Guerron
Alfredo D. Guerron
ASArpana Sali
Arpana Sali
GPGouri S. Pandey
Gouri S. Pandey
KNKanneboyina Nagaraju
Kanneboyina Nagaraju

16 May 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
CFCatherine A. Formolo
Catherine A. Formolo
RWRussell Williams
Russell Williams
HGHeather Gordish-Dressman
Heather Gordish-Dressman
TMTobey MacDonald
Tobey MacDonald
NLNorman H. Lee
Norman H. Lee
YHYetrib Hathout
Yetrib Hathout

1 November 2018 in Neuromuscular Disorders
Verified
Journal Article
Open access
CMCraig M. McDonald
Craig M. McDonald
HGHeather Gordish-Dressman
Heather Gordish-Dressman
EHErik K. Henricson
Erik K. Henricson
TDTina Duong
Tina Duong
NJNanette C. Joyce
Nanette C. Joyce
MTM. Thangarajh
M. Thangarajh
We describe changes in pulmonary function measures across time in Duchenne muscular dystrophy patients treated with glucocorticoids (GCs) > 1 year compared to GC naïve patients in the Cooperative International Research Group Duchenne Natural History Study, a multicenter prospective cohort study. 397 participants underwent 2799 pulmonary function assessments over a period up to 10 years. Fifty-three GC naïve participants (< 1 month exposure) were compared to 322 subjects with > 1 year cumulative GC treatment. Forced vital capacity (FVC), peak expiratory flow rate (PEFr), maximal inspiratory and expiratory pressures were performed and calculated as a percent predicted (%p). GC treatment slowed the rate of pulmonary decline as measured by FVC%p, in patients aged 7-9.9 years. GC treatment slowed 12 and 24-month progression of percent predicted spirometry to a greater degree in those with baseline FVC%p from < 80-34%. GC treatment resulted in higher peak absolute FVC and PEFr values with later onset of decline. Progression to an absolute FVC < 1 liter was delayed by GC treatment. Patients who reached a FVC below 1 L were 4.1 times more likely to die (p = 0.017). Long-term glucocorticoid treatment slows pulmonary disease progression in Duchenne dystrophy throughout the lifespan.

8 February 2011 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
CSChristopher Spurney
Christopher Spurney
ASArpana Sali
Arpana Sali
Alfredo Daniel GuerronAlfredo Daniel Guerron
Alfredo Daniel Guerron
MIMicaela Iantorno
Micaela Iantorno
QYQing Yu
Qing Yu
KNKanneboyina Nagaraju
Kanneboyina Nagaraju
Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice. In this study, C57BL/10ScSn-Dmdmdx/J female mice were either untreated or treated with losartan (n = 15) in the drinking water at a dose of 600 mg/L over a 6-month period. Cardiac function was assessed via in vivo high frequency echocardiography and skeletal muscle function was assessed using grip strength testing, Digiscan monitoring, Rotarod timing, and in vitro force testing. Fibrosis was assessed using picrosirius red staining and Image J analysis. Gene expression was evaluated using real-time polymerized chain reaction (RT-PCR). Percentage shortening fraction was significantly decreased in untreated (26.9% ± 3.5%) mice compared to losartan-treated (32.2% ± 4.2%; P < .01) mice. Systolic blood pressure was significantly reduced in losartan-treated mice (56 ± 6 vs 69 ± 7 mm Hg; P < .0005). Percentage cardiac fibrosis was significantly reduced in losartan-treated hearts (P < .05) along with diaphragm (P < .01), extensor digitorum longus (P < .05), and gastrocnemius (P < .05) muscles compared to untreated mdx mice. There were no significant differences in skeletal muscle function between treated and untreated groups. Chronic treatment with losartan decreases cardiac and skeletal muscle fibrosis and improves cardiac systolic function in dystrophin-deficient mdx mice.

9 January 2008 in Glia
Verified
Journal Article
Closed access
PDF file
ULUta Lichter‐Konecki
Uta Lichter‐Konecki
JMJean Marie Mangin
Jean Marie Mangin
HGHeather Gordish-Dressman
Heather Gordish-Dressman
Eric P HoffmanEric P Hoffman
Eric P Hoffman
VGVittorio Gallo
Vittorio Gallo